Sage Journals: Discover world-class research

Abstract

Lymphedema is an intractable disease with few effective therapeutic options. Autologous mesenchymal stem cell (MSC) transplantation is a promising therapy for this disease. However, its use is limited by the cost and time for preparation. Recently, xenotransplantation of porcine MSCs has emerged as an alternative to autologous MSC transplantation. In this study, we aimed to clarify the usefulness of neonatal porcine bone marrow–derived MSC (NpBM-MSC) xenotransplantation for the treatment of lymphedema. One million NpBM-MSCs were xenotransplanted into the hind limbs of mice with severe lymphedema (MSC transplantation group). The therapeutic effects were assessed by measuring the femoral circumference, the volume of the hind limb, the number and diameter of lymphatic vessels in the hind limb, and lymphatic flow using a near-infrared fluorescence (NIRF) imaging system. We compared the effects using mice with lymphedema that did not undergo NpBM-MSC transplantation (negative control group). The condition of the transplanted NpBM-MSCs was also evaluated histologically. The femoral circumference and volume of the hind limb had been normalized by postoperative day (POD) 14 in the MSC transplantation group, but not in the negative control group (P = 0.041). NIRF imaging revealed that lymphatic flow had recovered in the MSC transplantation group by POD 14, as shown by an increase in luminance in the hind limb. Histological assessment also showed that the xenotransplantation of NpBM-MSC increased the proliferation of lymphatic vessels, but they had been rejected by POD 14. The xenotransplantation of NpBM-MSCs is an effective treatment for lymphedema, and this is mediated through the promotion of lymphangiogenesis.

Keywords

lymphedema mesenchymal stem cell MSC pig xenotransplantation lymphangiogenesis vascular endothelial growth factor VEGF

Introduction

Lymphedema is characterized by lymphostasis in subcutaneous tissue, owing to impairment of the lymphatic system. The prevalence of this disease is increasing annually¹, and approximately 200 million people currently have lymphedema worldwide^2,3. Severe lymphedema contributes to a poor quality of life of the patients. For instance, foot lymphedema impedes walking⁴ and is a risk factor for refractory cellulitis and gangrene^5,6. Furthermore, long-term lymphedema can induce angiosarcoma, a malignant tumor derived from vascular and lymphatic endothelial cells (LECs)⁷. The current standard therapy for lymphedema is a combination of decompression therapies, including skin care, manual lymphatic drainage, compression using elastic stockings, and exercise⁸. However, these therapies are only palliative, and the therapeutic effects are unsatisfactory⁹.

Recently, mesenchymal stem cells (MSCs) have been determined to be promising cellular resources for regenerative medicine because they have useful characteristics, including multipotency; the potential for self-renewal¹⁰; and the production of growth factors and cytokines that promote angiogenesis and tissue regeneration and prevent fibrosis, apoptosis, and inflammation^11–14. In recent years, clinical trials of the use of MSC transplantation for the treatment of cardiovascular, cartilage, and neurological diseases have been performed^15–17.

MSCs also have a role in the promotion of lymphangiogenesis through differentiation into LECs and the production of growth factors¹⁸. This might render them suitable for the treatment of lymphedema. Indeed, a systematic review of the use of clinical autologous MSC transplantation for the treatment of lymphedema showed their usefulness and safety¹⁹. However, the use of autologous MSCs derived from lymphedema patients is limited by their poor quality, compared with those from healthy donors²⁰. In addition, autologous MSC transplantation has other limitations associated with their preparation. First, the acquisition of autologous MSCs is invasive because it involves bone marrow harvest and liposuction. Second, the preparation of autologous MSCs is expensive and time-consuming because it takes time to culture and prepare a sufficient number of MSCs for transplantation^21–23, as well as the requirement to prepare induced pluripotent stem (iPS) cell-derived biomaterials²⁴. Therefore, the establishment of alternative donor sources for MSCs is important to facilitate such treatment. We have focused on the use of neonatal porcine bone marrow–derived MSCs (NpBM-MSCs) as a promising candidate.

The pig is a promising donor candidate because of its similarity to humans and the established breeding methods²⁵. The immune response is the principal limitation of xenotransplantation, but recent progress in gene-editing technology might enable this limitation to be overcome and encourage the development of this approach. A recently reported case of porcine heart xenotransplantation showed that the innate immune response can be successfully avoided^26–28 and indicates that porcine xenotransplantation might be feasible in the near future. Porcine MSCs can be stored in a tissue bank, which enables them to be provided on demand. Furthermore, the neonatal pig is superior to the adult as a donor in terms of cost, scale, the retention of cell viability after culture, and cellular proliferation²⁹. Therefore, we consider that the development of NpBM-MSC xenotransplantation should contribute to the treatment of lymphedema.

In the present study, we aimed to clarify the usefulness of NpBM-MSC xenotransplantation for the treatment of lymphedema using a murine model of lymphedema that we have previously developed³⁰.

Materials and Methods

Study Design

The design of the study is shown in Fig. 1. In brief, one million NpBM-MSCs were xenotransplanted into a hind limb of mice with severe lymphedema (MSC transplantation group), then the effects were assessed by measurement of thigh circumference, the volume of the hind limb, number and diameter of the lymphatic vessels in the hind limb, and the lymphatic flow using a near-infrared fluorescence (NIRF) imaging system. Measurements of the femoral circumference were taken at three points that were considered to be the maximum diameter of the femoral region, and the maximum diameter of the three was used. And a piece of silk thread was wrapped around the femoral circumference, and its length was measured. Hind limb volume was measured by the water displacement method from the toes to the femoral region where the circumferential skin incision was performed. This method has been done in our previous and other research^5,7,30,31. The results were compared with those achieved in untreated mice with lymphedema (negative control group).

Figure 1.

Study design.

Animals and Ethics

Eight-week-old male C57BL/6J mice (Charles River Laboratories, Yokohama, Japan) were purchased, carefully monitored, and provided with a normal chow diet ad libitum. The animals were cared for, and the experimental procedures were performed in accordance with the Principles of Laboratory Animal Care of the Guide for the Care and Use of Laboratory Animals, 8th edition (National Research Council, 2011). The experimental protocol was approved by the Animal Care and Use Committee of Fukuoka University (approval number: 2113110). Regarding pain and distress categories, this study was classified as category C in our institution because animals used in this study had lymphedema for 4 weeks but prevented from severe stress with life-threatening complications.

Induction of Hind Limb Lymphedema

Lymphedema was induced in the mice using our previously published method³⁰. In brief, the mice were anesthetized using isoflurane (5% for induction, 2.4% for maintenance; Fujifilm Wako Pure Chemical Corporation, Osaka, Japan). After labeling the lymph vessels and nodes of the right hind limb by the subcutaneous injection of Evans blue (Fujifilm Wako Pure Chemical Corporation), a circumferential skin incision was made at the femoral region, and the labeled sub-iliac, popliteal, and sciatic lymph nodes and lymphatic vessels were dissected. The central side of the transected skin was cauterized, and the peripheral side was fixed to the myofascia using 6-0 nylon sutures (Johnson & Johnson, New Brunswick, NJ, USA) at four different sites. Irradition therapy was not included for making this model because of preventing damage of hind limb except lymphatic vessels.

Preparation of NpBM-MSCs

Primary NpBM-MSCs were kindly provided by Otsuka Pharmaceutical Factory, Inc. (Tokushima, Japan). These were obtained from nonclinical-grade neonatal pigs (age, 14 days; sex, male; body mass, 3.2 kg; Kadoi Ltd., Ibaraki, Japan) by Dr. Masuhiro Nishimura. We used three batches of the NpBM-MSCs in this study. They were used in different examinations including xenotransplantation, in vitro quality assessments (differentiation test and enzyme-linked immunosorbent assay [ELISA] for released growth factors), and assessment of LEC proliferation. The NpBM-MSCs were maintained in minimum essential medium α (Gibco, Waltham, MA, USA) containing 10% fetal bovine serum (Gibco), 100 U/mL penicillin and 100 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA), and 1 ng/mL human fibroblast growth factor-basic (Sigma-Aldrich; MSC culture medium) in 75-cm² flasks (Thermo Fisher Scientific, Inc, Waltham, MA, USA). The NpBM-MSCs were used at four passages.

Quality Assessment of the NpBM-MSCs

Before the transplantation of MSCs, we assessed the stem cell characteristics of the cells, which should be multipotent and able to produce cytokines and growth factors that have paracrine effects. Regarding multipotency, we attempted to induce their differentiation into adipocytes or osteoblasts using an adipocyte differentiation kit (Bio Future Technology, Tokyo, Japan) or an osteoblast differentiation kit (Bio Future Technology). Adipocytes and osteoblasts were identified using oil red O and Alizarin Red S (Bio Future Technology) staining, respectively. The culture medium used to incubate NpBM-MSCs was collected after 24 h for the assessment of vascular endothelial growth factor (VEGF)-A, VEGF-C, and transforming growth factor beta (TGF-β) secretion. The number of seeded cells and the volume of culture medium were 1 × 10⁵ cells and 2 mL per well, respectively. The VEGF-A, VEGF-C, and TGF-β1 concentrations in the medium were measured before culture to determine the basal amounts of cytokine present in the medium. These concentrations were measured by ELISA using a Porcine Vascular Endothelial Growth Factor A ELISA Kit (MyBioSource, Inc, San Diego, CA, USA), a Porcine Vascular Endothelial Growth Factor C ELISA Kit (MyBioSource, Inc), a Mouse VEGF-A ELISA kit (Novus Biological, Centennial CO, USA), a Mouse VEGF-C ELISA kit (Novus Biological), and porcine and murine TGF-β1 ELISA kits (Proteintech Japan, Tokyo, Japan). The basal concentrations in the media were subtracted from the postincubation concentrations, and the resulting concentrations were normalized to the number of cells present at the time of sample collection. The data are expressed per 1 × 10⁵ cells.

Assessment of LEC Proliferation

C57BL/6J-derived LECs (Cell Biologics, Inc, Chicago IL, USA) at seven passages were seeded into wells in NpBM-MSC–conditioned medium, alongside wells containing nonconditioned medium. NpBM-MSC–conditioned medium was prepared using 10 mL of endothelial cell basal medium (Lonza, Basel, Switzerland) containing 0.5% fetal bovine serum (FBS) by culturing with NpBM-MSCs at 1.0 × 10⁶ cells per 75-cm² flask for 24 h. Each well of a six-well plate was seeded with 1.0 × 10⁵ cells, and after 24 h, the cells were trypsinized, and the total number of cells and number of dead cells were counted.

Three-Dimensional Culture of LECs

LECs were cultured using an EGM-2 Endothelial Cell Growth Medium-2 Bulletkit (Lonza) and used for in vitro experiments after seven passages. The formation of three-dimensional capillary-like structures was assessed using a Matrigel-based tube formation assay³². LECs were embedded in growth factor–reduced Matrigel (Corning, Corning, NY, USA) (5 × 10⁴ cells/50 µL) and incubated (MSC medium group). As a control, LECs cultured in the absence of Matrigel were prepared as medium-only group. The cells were incubated at 37°C in a 5% CO₂-containing atmosphere for 14 days. Tube formation was assessed using a BZ-X700 fluorescence microscope (Keyence, Itasca, IL, USA) and Image J v1.54e software (NIH, Bethesda, MD, USA; available at https://imagej.net) in five random fields every other day. To quantify this, the sum of the long-axis length of all the LECs and the number of branching points per field at ×100 magnification were measured.

MSC Xenotransplantation and Animal Groups

MSC xenotransplantation was performed in mice 7 days after the induction of lymphedema. NpBM-MSCs (1 × 10⁶ cells) suspended in 100-µL phosphate-buffered saline (PBS, Gibco) were injected at three locations (cranial, lateral, and caudal aspects, Fig. 1) in the femoral muscle using a 27-gauge needle under general anesthesia induced and maintained using isoflurane. Mice in the MSC xenotransplantation group were administered NpBM-MSCs, and mice in the negative control group were injected with the same volume of PBS. We also prepared a normal group consisting of mice that were untreated.

Measurements of Femoral Circumference and Hind Limb Volume

The degree of lymphedema of the mice was evaluated by measuring their femoral circumference and the volume of their hind limbs using the water displacement method^5,7,31. Successful induction of lymphedema was accepted if there was an increase in the circumference or volume of the hind limb of >10% vs those before surgery.

Histological Assessment of the Hind Limb

Histological assessments of the number, maximum short-axis diameter, and total area of lymphatic vessels of the hind limb were conducted and measured using a BZ-X700 fluorescence microscope (Keyence) and software (Hybrid Cell Count) of the BZ-X700 fluorescence microscope (Keyence). The data acquired by Keyence are able to automatically measure number, maximum short-axis diameter, and total area. Femoral samples were excised from some of the mice in the normal, negative control, and MSC transplantation groups on postoperative day (POD) 0 (the day of MSC transplantation) and PODs 7, 14, 21, and 28. Three slides of the largest section of the mouse hind limb femoral region (n = 10) were used for histological assessment. The samples were fixed using 10% formaldehyde solution, embedded in paraffin, and cut into 3-µm-thick sections. They were then subjected to heat-induced epitope retrieval, blocking by incubation in Blocking One Histo (Nacalai Tesque, Kyoto, Japan) for 30 min at room temperature, and incubation with primary antibodies. The primary antibodies were purified hamster anti-podoplanin (Pdp, 1:100; BioLegend, San Diego, CA, USA), for the identification of lymphatic vessels, and mouse anti-pig swine leukocyte antigen (SLA) class I (1:100; Bio-Rad Laboratories Inc., Hercules, CA, USA), for the identification of transplanted NpBM-MSCs²³. The secondary antibody was goat anti-hamster IgG (H + L) Alexa Fluor 546 (Invitrogen, Carlsbad, CA, USA). Samples were incubated with primary antibodies for 2 h at room temperature and with secondary antibody for 2 h in the dark at 37°C. Images were acquired using a BZ-X700 fluorescence microscope (Keyence). Pdp-positive cells were regarded as being part of lymphatic vessels, and the number, diameter, and area of each were calculated as the mean values for five different fields of view at ×100 magnification using BZ-X700 software (Hybrid Cell Count).

Measurement of Lymphatic Flow Using NIRF Imaging

The subcutaneous tissue of a hind limb of each mouse in both the MSC and negative control groups was injected with 10 μl of indocyanine green (ICG, 2.5 mg/mL; Daiichi Sankyo, Tokyo, Japan) under general anesthesia using isoflurane. The lymphatic flow in the hind limb was then measured using a NIRF imaging system (Pde-neo; Hamamatsu Photonics, Shizuoka, Japan). The measurement conditions (external light, such as fluorescent light, and the brightness and contrast of the photodynamic eye [PDE]) were standardized before commencing these measurements. The lymphatic flow was measured weekly from the date of induction of lymphedema to the fourth week following NpBM-MSC xenotransplantation as luminance using image J v1.54e software (NIH). Luminance was calculated as the corrected total cell fluorescence (CTCF) using the following formula^24,25,33,34:

CTCF = Integrated density - (\begin{array}{l} Area of selected cell \times \\ Mean background \\ fluorescence \end{array})

However, we modified this by including the noncell fluorescence in the equation. The mean relative luminance was determined by dividing the CTCF by the area of fluorescence, as follows:

\begin{array}{l} CTCF / area : CTCF = (integrated density - \\ (\begin{array}{l} area of selected region \times \\ mean fluorescence of five \\ background readings \end{array}) / area of the selected region . \end{array}

Real-Time Quantitative Polymerase Chain Reaction

The hind limbs of some of the mice in the three groups were collected on PODs 0, 7, 14, 21, and 28 for the quantitative polymerase chain reaction (qPCR) analysis of the hind limb tissues other than bone. After removing the bones, the tissues were homogenized together using a homogenizer (T10 basic; IKA Japan, Osaka, Japan) in TRIzol reagent (Invitrogen), then RNA was extracted. The concentrations of the mRNA samples obtained were measured using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc) and then equalized. cDNA was synthesized from this RNA using a PrimeScript Plus RT Kit (Takara Biotechnology Co., Ltd., Kusatsu, Japan), in accordance with the manufacturer’s instructions.

qPCR was performed using the StepOnePlus Real-time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc, Waltham, MA, USA) and a SYBR green assay. The porcine and murine primers used for the qPCR are shown in Table 1. Relative quantification of target mRNAs was performed using StepOne Software v.2.3 (Applied Biosystems, Inc), and the results were normalized to the expression of the reference gene Actb. All the reactions were performed in triplicate, and quantification was performed using the 2^−ΔΔCT method.

Table 1.

Primer Information.

Mouse
		Sequence (5′ - 3′)	Tm (°C)
Actb	Forward	CATCCGTAAAGACCTCTATGCCAAC	53.9
	Reverse	ATGGAGCCACCGATCCACA	49.4
Vegfa	Forward	ACATTGGCTCACTTCCAGAAACAC	63.8
	Reverse	TGGTTGGAACCGGCATCTTTA	64.7
Vegfc	Forward	CAGTGCATGAACACCAGCACA	64.4
	Reverse	TAGACATGCACCGGCAGGAA	65
Vegfd	Forward	GTTGTAAGTGCTTGCCCACG	65.5
	Reverse	CCTGGAGGTAAGAGTGGTCTTCTG	66.1
Tgfb1	Forward	GTGTGGAGCAACATGTGGAACTCTA	53.9
	Reverse	CGCTGAATCGAAAGCCCTGTA	50.5
Pigs
Gene		Sequence (5′ - 3′)	Tm (°C)
Actb	Forward	CGACTGCGCCCCATAAAACC	52.0
	Reverse	GTCATCCATGGCGAACTGGT	50.0
Vegfa	Forward	GCATTGGAGCCTTGCCTTGC	71.1
	Reverse	GTCCATGAACTTCACCACTTCGT	66.2
Vegfc	Forward	CCTGCCCAAGAAATCAACCCT	68.1
	Reverse	ACGGTCGTCTGTAACAACTGC	64.0
Vegfd	Forward	TCCCCTTGCTGGAATGGAAGATCA	73.2
	Reverse	GCTGCAGTTTTCTGGGTGCT	66.6
Tgfb1	Forward	TGGAAAGCGGCAACCAAATC	59.7
	Reverse	AGAGCAATACAGGTTCCGGC	60.1

Statistical Analysis

Data are presented as mean ± standard error of the mean. Statistical comparisons of two groups were made using Student’s t-test; and ANOVA, followed by Tukey’s HSD test, was used for multiple groups. P < 0.05 was considered to represent statistical significance. All analyses were performed using SPSS v.24 (IBM Corp., Armonk, NY, USA).

Results

NpBM-MSCs Promote the Proliferation of LECs Via the Secretion of VEGFs

First, we characterized the NpBM-MSCs. The NpBM-MSCs were able to differentiate into osteocytes and adipocytes (Fig. 2A, B). They also secreted porcine VEGF-A and VEGF-C into the culture medium (113.8 ± 6.9 pg/ mL vs 0.0 ± 0.0 pg/ mL [P < 0.0001] and 110.4 ± 1.9 pg/ mL vs 0.0 ± 0.0 pg/ mL [P < 0.0001], respectively, vs cell-free medium; Fig. 2C, D). However, neither murine VEGF-A nor VEGF-C was detected in the NpBM-MSC–conditioned medium (Fig. 2F, G). The cells also secreted porcine TGF-β1 into the culture medium (139.2 ± 4.6 pg/ mL vs 0.0 ± 0.1 pg/ mL, P < 0.0001, vs cell-free medium; Fig. 2E). Furthermore, the proliferation of LECs was promoted by culture with the NpBM-MSC–conditioned medium (15.3 ± 0.4 × 10⁴ cells vs 20.2 ± 1.4 × 10⁴ cells after 24 h, P < 0.01; Fig. 2H). Tube formation, which was defined as the presence of a tube-shaped structure consisting of LECS that had proliferated and budded, was also promoted by incubation with the NpBM-MSC–conditioned medium (Fig. 2I). Both the total length of the long axes of the LECs and the number of branching points per field were significantly larger in cells incubated in NpBM-MSC–conditioned medium (4,970.0 ± 354.7 vs 3,358.6 ± 312.7 μm/field after 72 h, P < 0.01; and 29.8 ± 1.8 vs 20.7 ± 1.7 points/field after 72 h, P < 0.001; respectively; Fig. 2J, K).

Figure 2.

Characteristics of NpBM-MSCs as promoters of lymphangiogenesis. Multipotency of the NpBM-MSCs: differentiation into osteoblasts (A) and adipocytes (B). Concentrations of porcine VEGF-A (C), VEGF-C (D), and TGF-β1 (E) in the NpBM-MSC medium after 24 h of culture. Concentrations of murine VEGF-A (F) and VEGF-C (G) in the NpBM-MSC medium. (H) Number of cultured LECs after incubation with the NpBM-MSC–conditioned medium. The number of seeded cells was 1 × 10⁴ cells. (I) LECs after 3D culture with nonconditioned medium (upper panel) and NpBM-MSC–conditioned medium (lower panel) for 72 h. (J) The sum of the long-axis lengths of the LECs per field (×100). (K) Branching points per field (×100). Scale bars = 50 µm (A and B), 200 µm (I). Nonconditioned medium (red) and MSC-conditioned medium (purple). n = 6 per group. *P < 0.01, **P < 0.001, ***P < 0.0001.

NpBM-MSC Xenotransplantation Ameliorates Lymphedema Via the Promotion of Lymphangiogenesis and a Recovery of Lymphatic Flow

Next, we evaluated the potential therapeutic effects of NpBM-MSCs using the lymphedema model. Fig. 3A shows the changes in hind limb lymphedema that occurred following NpBM-MSC transplantation. All the mice in both the negative control and MSC transplantation groups developed lymphedema, showing increases in hind limb circumference and volume 7 days after the induction, at the time of MSC transplantation (POD 0). In the MSC transplantation group, significant amelioration of the lymphedema was apparent on POD 7 (Fig. 3A), and the femoral circumference and volume of these mice were significantly smaller (had been normalized) on POD 14. In contrast, the lymphedema was worse in the negative control group on POD 7 (Fig. 3A). This gradually improved with time, but neither the femoral circumference nor volume normalized. The mean femoral circumferences on POD 14 were 46.7 ± 1.1 vs 39.8 ± 0.7 mm, respectively (P < 0.01; Fig. 3B), and the hind limb volumes on the same day were 203.2 ± 7.5 vs 128.2 ± 4.7 mm³, respectively (P < 0.001; Fig. 3C). Both the circumference and volume of the hind limbs of the MSC transplantation group remained smaller than those of the negative control group (Fig. 3B, C).

Figure 3.

Assessment of mouse hind limbs following NpBM-MSC xenotransplantation. (A) Changes in the hind limbs of mice following the induction of lymphedema and NpBM-MSC xenotransplantation. Left panel: negative control group; right panel: MSC transplantation group. The date of induction was defined as postoperative day (POD) −7, and the date of MSC transplantation as POD 0. Thigh circumference (B) and hind limb volume (C) of the negative control (red), MSC transplantation (purple), and normal (gray) groups. n = 10 per group. *P < 0.05, **P < 0.01, ***P < 0.001.

Next, we assessed the lymphatic flow in the hind limbs of the mice to evaluate the therapeutic effects of NpBM-MSC transplantation using the NIRF imaging system. In this way, we visualized the ICG-enhanced lymphatic vessels and lymph nodes in the hind limbs of the mice in the normal group (Fig. 4A). In the MSC transplantation group, the lymphatic flow was visualized on the central side of the excised area of skin on POD 14. In addition, with reference to the commonly used classification of the severity of lymphedema, the negative control group showed a stardust or diffuse pattern on POD 14 (Fig. 4B), which is considered to reflect severe lymphedema. However, the MSC transplantation group showed a linear pattern, indicative of the recovery of lymphatic flow and amelioration of the edema (Fig. 4B). On POD 28, the luminance at the site was maximal. On POD 28 in particular, the MSC transplantation group showed not only greater but also more extensive luminance than the negative control group (Fig. 4B). The CTCF/area was significantly higher after POD 14, and peaked at POD 28, in the MSC transplantation group (10.3 ± 1.0 vs 3.9 ± 0.6, P < 0.01; Fig. 4C).

Figure 4.

Assessment of lymphatic flow in the hind limbs of the mice using near-infrared fluorescence (NIRF) imaging. (A) NIRF images of a hind limb from the normal group. Left panel: cranial aspect; right panel: caudal aspect. (B) NIRF images of a hind limb on PODs −7, 14, and 28 from the negative control (upper panel) and MSC transplantation (lower panel) groups. (C) Quantification of fluorescence in the hind limbs of negative control and MSC transplantation groups using ImageJ, as CTCF/area (integrated density − (area of selected region × mean fluorescence of five background readings)/area of the selected region). *P < 0.05, **P < 0.01.

Fig. 5A shows the histological images of the lymphatic vessels in the hind limbs of the mice, stained for Pdp. These showed that the number of lymphatic vessels in the MSC transplantation group gradually increased with time and was significantly larger than that in the negative control group after POD 14 (Fig. 5A, B). Regarding the maximum short-axis diameter of the lymphatic vessels, which is indicative of the dilation of the lymphatic vessels, it became larger in the negative control group than in the normal group. The diameters of the MSC transplantation group were also significantly larger than those of the negative control group on PODs 7 and 14 (P < 0.05 and < 0.001, respectively; Fig. 5A and C). We consider this dilation was reflected on the promotion of lymphatic drainage and removal of internal pressure in the hind limb with lymphedema. Furthermore, the total area of the lymphatic vessels was significantly larger in the MSC transplantation group than that in the negative control group on the same days (P < 0.001; Fig. 5A, D).

Figure 5.

Histological assessment of mouse lymphatic vessels after MSC transplantation. (A) Immunofluorescence staining for podoplanin (red) in thigh samples obtained from mice in the negative control (upper), MSC transplantation (middle), and normal (lower) groups on PODs 7, 14, and 28. Scale bars: 100 µm. The number (B), maximum short-axis diameter (C), and total area (D) of lymphatic vessels in the negative control (red), MSC transplantation (purple), and normal (gray) groups. n = 10 per group. *P < 0.05, **P < 0.01.

These data indicate that NpBM-MSC xenotransplantation ameliorates lymphedema by promoting lymphangiogenesis in the hind limbs of mice, facilitating the recovery of lymphatic flow at the site of the intervention.

Xenotransplanted NpBM-MSCs Increase the Expression of Both Porcine and Murine VEGFs Until They Are Rejected

We next assessed the condition of the NpBM-MSCs following xenotransplantation. Fig. 6A shows the transplanted NpBMs, stained for SLA class I, in the hind limb. NpBM-MSCs were identified on both POD 3 and 7, but there were fewer on POD 14. However, there were no SLA class I-positive cells in the hind limbs of the negative control group (Fig. 6B). Therefore, we speculate that the NpBM-MSCs were viable and facilitated lymphangiogenesis by POD 7 but had been rejected by POD 14.

Figure 6.

Assessment of the engraftment and rejection of xenotransplanted porcine MSCs. (A) Histological findings associated with transplanted NpBM-MSCs, immunostained for swine leukocyte antigen (SLA) class I, in the hind limbs of mice in the MSC transplantation group on PODs 3, 7, and 14. (B) Equivalent findings for the negative control group on POD3. Scale bars: 50 µm.

We next evaluated the expression of VEGF genes in the hind limbs of the mice. Fig. 7 shows the relative expression of porcine and murine VEGF-A, VEGF-C, and VEGF-D and TGF-β1 mRNAs in the hind limbs of the negative control, MSC transplantation, and normal groups. The expression of porcine Vegfa, Vegfc, Vegfd, and Tgfb1 was not detected in the negative control and normal groups (Fig. 7A–D). However, the expression of porcine Vegf and Tgfb1 was present on POD 1 in the MSC transplantation group. Although the expression of Vegfa and Vegfd was lower on POD 3 (Fig. 7A, C), that of porcine Vegfc and Tgfb1 continued to increase until POD 7 (Fig. 7B, D). Furthermore, NpBM-MSC xenotransplantation affected the expression of murine Vegf genes. Although an increase in the expression of murine Vegf genes was identified in the negative control group, the expression in the MSC transplantation group was higher (murine Vegfa: P < 0.05 on POD 1, P < 0.05 on POD 3; murine Vegfc: P < 0.01 on POD 1, P < 0.01 on POD 3; murine Vegfd: P < 0.05 on POD 3; murine Tgfb1: P < 0.05 on POD 3; Fig. 7E–H). The expression of murine Vegf genes other than Vegfc and Tgfb1 in the MSC transplantation group was lower after POD 7, and that of murine Vegfc was also low on POD 14.

Figure 7.

Expression of genes encoding lymphangiogenetic factors at the transplantation site. mRNA expression of porcine VEGF-A (A), VEGF-C (B), VEGF-D (C), and TGF-β1 (D). mRNA expression of murine VEGF-A (E), VEGF-C (F), VEGF-D (G), and TGF-β1 (H) in the thighs of mice in the normal (gray), negative control (red), and MSC transplantation (purple) groups on PODs 0, 1, 3, 7, and 14. Expression was quantified using the 2^−ΔΔCT method, and Actb was used as the reference gene. n = 6. *P < 0.05, **P < 0.01, ***P < 0.001.

In summary, NpBM-MSC xenotransplantation increases the expression of not only the porcine but also the murine Vegf genes, and especially of Vegfc, until rejection.

Discussion

In the present study, we have shown that NpBM-MSC xenotransplantation corrects lymphedema within 14 days using our mouse model of lymphedema, and this effect persists for over a month³⁰. The therapeutic effects of the NpBM-MSC xenotransplantation were found to be exerted through the paracrine promotion of lymphangiogenesis. We found that NpBM-MSCs secrete angiogenic and lymphangiogenic factors, including VEGF-A, VEGF-C, and TGF-β1 and increase the expression of porcine Vegf genes and Tgfb1 at the transplantation sites, until they are rejected, at approximately POD 14. VEGF-C is a representative lymphangiogenic factor that induces both angiogenesis and lymphangiogenesis and promotes lymphatic sprouting³⁵. Furthermore, the xenotransplantation of NpBM-MSCs increases the expression of genes encoding not only porcine but also murine growth factors. As a result, the resolution of intestinal edema might be caused by a recovery of lymphatic flow and an amelioration of lymphedema. Thus, MSC transplantation has beneficial effects on lymphedema in mice over a significant period of time despite their rejection approximately 2 weeks after transplantation. We made similar findings in our previous study, which revealed the beneficial effects of xenogeneic NpBM-MSCs in a model of lower-limb ischemia³⁶.

The xenotransplanted NpBM-MSCs were viable at the site of transplantation for at least 7 days, produced growth factors including VEGF-C, and initiated lymphangiogenesis locally. After the initiation of lymphangiogenesis, the transplanted NpBM-MSCs were eliminated by the immune responses of the recipient animals. However, sustained lymphangiogenesis was achieved through an increase in the production of growth factors by the recipient. Indeed, as shown in Fig. 6, greater production of murine VEGFs occurred at the same time as the expression of porcine VEGFs, which might have contributed to the subsequent lymphangiogenesis³⁷. We speculate that porcine NpBM-MSCs might directly promote lymphangiogenesis via the secretion of endogenous VEGFs and indirectly contribute to this lymphangiogenesis via the production of such growth factors in recipient tissues, including by fibroblasts, myocytes, and lymphatic vessels³². These indirect effects might be important therapeutically because the direct effects on the secretion of porcine VEGFs are transient, owing to the rejection of the transplanted cells.

Some studies have considered that porcine growth factors, including TGF-β1, induce angiogenesis through the upregulation of VEGFs^38,39, which are secreted by cells at the transplantation site, thereby indirectly supporting lymphangiogenesis. The long-lasting lymphangiogenetic effect of NpBM-MSC xenotransplantation is a desirable characteristic of an agent for the treatment of lymphedema. In contrast to autologous MSCs, porcine MSCs can be administered whenever required. If the safety of porcine cell administration, such as the prevention of zoonosis owing to porcine endogenous retrovirus^40,41, can be established, this approach may represent a suitable option for the treatment of lymphedema. Furthermore, the therapeutic effects of NpBM-MSCs might be prolonged by the use of gene-edited pigs in which carbohydrate antigens are eliminated, and the innate immune response is prevented²⁸. For the success of the xenotransplantation of NpBM-MSCs, quality control is important, including the culture medium conditions, the transplantation technique, the age of the donor, and the duration of culture^42,43. Regarding the quality control, measurement of repressor/activator protein (Rap) 1 before NpBM-MSCs transplantation can be a useful parameter. Recent studies have shown that status of MSC is tightly regulated by telomerase-associated proteins Rap1/nuclear factor-kappaB (NF-κB) signaling pathway. They revealed that this signaling pathway in MSCs regulated the paracrine effects⁴⁴, and Rap1 deficiency attenuated paracrine effects leading to impairment of immunosuppressive potency⁴⁵. Therefore, it would be informative to check RAP1 level in NpBM-MSCs for prediting the outcome of the transplantation. Furthermore, the extension of the lifespan of grafts will be a pivotal challenge with respect to the sustainable therapeutic effects of xenotransplanted NpBM-MSCs. And it is the limitation of this study. The extension of the graft survival without rejection would contribute to the cure of lymphedema. We consider that this might be feasible in the near future through the use of gene-edited pigs, as shown in recent clinical trials of porcine heart xenotransplantation^28,46.

As the other limitation, we have no data showing the differentiation of NpBM-MSCs into lymphatic vessels. Previous studies anout MSC therapy for heart failure indicated that transplanted MSCs promoted endogenous myocardial regenerartion, angiogenesis, and immunomodulation via paracrine effects^47,48. On the other hand, Lian et al.⁴⁹ showed transplanted iPS cells–derived MSCs induced vascular and muscle regeneration via both direct differentiation and paracrine mechanisms in their limb ischemia model. We predicted that xenotransplanted NpBM-MSCs were rejected before engraftment and differentiation; however, the assessment about direct differentiation will be done in future study.

We consider that these therapeutic effects of NpBM-MSCs are seen in MSCs derived from other tissue, especially adipose tissue. For example, Ogino et al.⁵⁰ attempted to elucidate the therapeutic effects of adipose-derived stem cell (ADSC) transplantation for lymphedema animal model. They showed that ADSC transplantation promoted lymphangiogenesis and compromised fibrosis in hind limb with lymphedema via upregulation of Tgfb1 and downregulation of Colla1⁵⁰.

In conclusion, the xenotransplantation of NpBM-MSCs ameliorates lymphedema in mice. We consider that this approach will be a reliable option for the clinical treatment of lymphedema in the future.

Footnotes

Acknowledgements

The authors thank Ms. Yuriko Hamaguchi for performing the ELISAs. They also thank Edanz () for English language editing.

Data availability statement

The data that support the findings of this study are available from the corresponding author (NS and SK), upon reasonable request.

Ethical Approval

The animals were cared for and the experimental procedures were performed in accordance with the Principles of Laboratory Animal Care of the Guide for the Care and Use of Laboratory Animals, 8th edition (National Research Council, 2011). The experimental protocol was approved by the Animal Care and Use Committee of Fukuoka University (approval number: 2113110).

Statement of Human and Animal Rights

This article does not contain any studies with human or animal subjects.

Statement of Informed Consent

There are no human subjects in this article, and informed consent is not applicable.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by an intramural grant to SK.

ORCID iDs

Naoaki Sakata

Masuhiro Nishimura

Osamu Sawamoto

Shohta Kodama

References

Kurt

Arnold

Payne

Miller

Skoracki

Iwenofu

. Massive localized lymphedema: a clinicopathologic study of 46 patients with an enrichment for multiplicity. Mod Pathol. 2016;29(1):75–82.

Rockson

Rivera

. Estimating the population burden of lymphedema. Ann N Y Acad Sci. 2008;1131:147–54.

Allam

Park

Chandler

Mozaffari

Ahmad

Alperovich

. The impact of radiation on lymphedema: a review of the literature. Gland Surg. 2020;9(2):596–602.

Brown

John

Segal

Chu

Schmitz

. Physical activity and lower limb lymphedema among uterine cancer survivors. Med Sci Sports Exerc. 2013;45(11):2091–97.

Nakajima

Asano

Mukai

Urai

Okuwa

Sugama

Nakatani

. Near-infrared fluorescence imaging directly visualizes lymphatic drainage pathways and connections between superficial and deep lymphatic systems in the mouse hindlimb. Sci Rep. 2018;8(1):7078.

Harb

Levi

Corvi

Nicolas

Zheng

Chaudhary

Akelina

Connolly

Ascherman

. Creation of a rat lower limb lymphedema model. Ann Plast Surg. 2020;85(suppl 1):S129–34.

Jun

Lee

Kim

Noh

Kwon

Cho

Yoon

. Modified mouse models of chronic secondary lymphedema: tail and hind limb models. Ann Vasc Surg. 2017;43:288–95.

Will

Rafiei

Pretze

Gazyakan

Ziegler

Kneser

Engel

Wängler

Kzhyshkowska

Hirche

. Evidence of stage progression in a novel, validated fluorescence-navigated and microsurgical-assisted secondary lymphedema rodent model. PLoS ONE. 2020;15(7):e0235965.

Iwasaki

Yamamoto

Murao

Oyama

Funayama

Furukawa

. Establishment of an acquired lymphedema model in the mouse hindlimb: technical refinement and molecular characteristics. Plast Reconstr Surg. 2017;139(1):67e–78e.

10.

Potten

Loeffler

. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development. 1990;110(4):1001–20.

11.

Chen

Shao

Xiang

Dong

Zhang

. Mesenchymal stem cells: a promising candidate in regenerative medicine. Int J Biochem Cell Biol. 2008;40(5):815–20.

12.

Meirelles Lda

Fontes

Covas

Caplan

. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20(5–6):419–27.

13.

Hocking

Gibran

. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Exp Cell Res. 2010;316(14):2213–19.

14.

Linero

Chaparro

. Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration. PLoS ONE. 2014;9(9):e107001.

15.

Petrou

Kassis

Levin

Paul

Backner

Benoliel

Oertel

Scheel

Hallimi

Yaghmour

Hur

, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020;143(12):3574–88.

16.

Lee

Kim

Jin

. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504–11.

17.

Bolli

Perin

Willerson

Yang

Traverse

Henry

Pepine

Mitrani

Hare

Murphy

March

, et al. Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial. JACC Cardiooncol. 2020;2(4):581–95.

18.

Roh

Cho

Park

Yoo

Kim

Park

Kang

Yeom

Lee

, et al. Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model. Exp Biol Med. 2017;242(6):584–92.

19.

Lafuente

Jaunarena

Ansuategui

Lekuona

Izeta

. Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):578.

20.

Brix

Sery

Onorato

Ure

Roessler

Goswami

. Biology of lymphedema. Biology. 2021;10(4):261.

21.

Secunda

Vennila

Mohanashankar

Rajasundari

Jeswanth

Surendran

. Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study. Cytotechnology. 2015;67(5):793–807.

22.

Mastrolia

Foppiani

Murgia

Candini

Samarelli

Grisendi

Veronesi

Horwitz

Dominici

. Challenges in clinical development of mesenchymal stromal/stem cells: concise review. Stem Cells Transl Med. 2019;8(11):1135–48.

23.

Khatri

Richardson

Meulia

. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018;9(1):17.

24.

BustamanteLopez

Meissner

. Characterization of carrier erythrocytes for biosensing applications. J Biomed Opt. 2017;22(9):91510.

25.

Fowler

Garmon

Fessler

Ogle

Grover

Allen

Williams

Zhou

Yazdanifar

Ogle

Mukherjee

. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. BMC Cancer. 2018;18(1):457.

26.

Carrier

Verma

Mohiuddin

Pascual

Muller

Longchamp

Bhati

Buhler

Maluf

Meier

RPH

. Xenotransplantation: a new era. Front Immunol. 2022;13:900594.

27.

Jiang

Liu

. Xenogeneic stem cell transplantation: research progress and clinical prospects. World J Clin Cases. 2021;9(16):3826–37.

28.

Griffith

Goerlich

Singh

Rothblatt

Lau

Shah

Lorber

Grazioli

Saharia

Hong

Joseph

, et al. Genetically modified porcine-to-human cardiac xenotransplantation. N Engl J Med. 2022;387(1):35–44.

29.

Nishimura

Nguyen

Watanabe

Fujita

Sawamoto

Matsumoto

. Development and characterization of novel clinical grade neonatal porcine bone marrow-derived mesenchymal stem cells. Xenotransplantation. 2019;26(3):e12501.

30.

Morita

Sakata

Kawakami

Shimizu

Yoshimatsu

Wada

Kodama

. Establishment of a simple, reproducible, and long-lasting hind limb animal model of lymphedema. Plast Reconstr Surg Glob Open. 2023;11(9):e5243.

31.

Park

Jung

Choi

Hahn

Yoo

Lee

. Modification of a rodent hindlimb model of secondary lymphedema: surgical radicality versus radiotherapeutic ablation. Biomed Res Int. 2013;2013:208912.

32.

Kivelä

Havas

Vihko

. Localisation of lymphatic vessels and vascular endothelial growth factors-C and -D in human and mouse skeletal muscle with immunohistochemistry. Histochem Cell Biol. 2007;127(1):31–40.

33.

Marcazzan

Braz Carvalho

Konrad

Strangmann

Tenditnaya

Baumeister

Schmid

Wester

Ntziachristos

Gorpas

Wang

, et al. CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett’s esophagus. EJNMMI Res. 2022;12(1):2.

34.

Chang

Lee

Jung

Kim

Woo

Lee

Son

. Sentinel lymph node detection using fluorescein and blue light-emitting diodes in patients with breast carcinoma: a single-center prospective study. Asian J Surg. 2020;43(1):220–26.

35.

Sweat

Sloas

Murfee

. VEGF-C induces lymphangiogenesis and angiogenesis in the rat mesentery culture model. Microcirculation. 2014;21(6):532–40.

36.

Yamada

Naito

Nishimura

Kawakami

Morinaga

Morita

Shimizu

Yoshimatsu

Sawamoto

Matsumoto

Imafuku

, et al. Xenotransplantation of neonatal porcine bone marrow-derived mesenchymal stem cells improves diabetic wound healing by promoting angiogenesis and lymphangiogenesis. Xenotransplantation. 2022;29(2):e12739.

37.

Scallan

Zawieja

Castorena-Gonzalez

Davis

. Lymphatic pumping: mechanics, mechanisms and malfunction. J Physiol. 2016;594(20):5749–68.

38.

Zhao

Meng

Liu

Chen

Sun

. Vascular endothelial growth factor-C: its unrevealed role in fibrogenesis. Am J Physiol Heart Circ Physiol. 2014;306(6):H789–96.

39.

Shimizu

Yoshimatsu

Morita

Tanaka

Sakata

Tagashira

Wada

Kodama

. Rescue of murine hind limb ischemia via angiogenesis and lymphangiogenesis promoted by cellular communication network factor 2. Sci Rep. 2023;13(1):20029.

40.

Patience

Takeuchi

Weiss

. Infection of human cells by an endogenous retrovirus of pigs. Nat Med. 1997;3(3):282–86.

41.

Specke

Rubant

Denner

. Productive infection of human primary cells and cell lines with porcine endogenous retroviruses. Virology. 2001;285(2):177–80.

42.

Lee

Choi

Cha

Hwang

. Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy. Oxid Med Cell Longev. 2015;2015:632902.

43.

Garcia-Sanchez

Fernandez

Rodriguez-Rey

Perez-Campo

. Enhancing survival, engraftment, and osteogenic potential of mesenchymal stem cells. World J Stem Cells. 2019;11(10):748–63.

44.

Zhang

Chiu

Liang

Gao

Zhang

Liao

Liang

Chai

Low

Tse

Tergaonkar

, et al. Rap1-mediated nuclear factor-kappaB (NF-kappaB) activity regulates the paracrine capacity of mesenchymal stem cells in heart repair following infarction. Cell Death Discov. 2015;1:15007.

45.

Ding

Liang

Zhang

Shum

Chen

Chan

Fan

Liu

Tergaonkar

, et al. Rap1 deficiency-provoked paracrine dysfunction impairs immunosuppressive potency of mesenchymal stem cells in allograft rejection of heart transplantation. Cell Death Dis. 2018;9(3):386.

46.

Moazami

Stern

Khalil

Kim

Narula

Mangiola

Weldon

Kagermazova

James

Lawson

Piper

, et al. Pig-to-human heart xenotransplantation in two recently deceased human recipients. Nat Med. 2023;29(8):1989–97.

47.

Liao

Zhang

Ting

Zhen

Luo

Zhu

Jiang

Sun

Lai

Lian

Tse

. Potent immunomodulation and angiogenic effects of mesenchymal stem cells versus cardiomyocytes derived from pluripotent stem cells for treatment of heart failure. Stem Cell Res Ther. 2019;10(1):78.

48.

Sun

Lai

Jiang

Zhen

Wei

Lian

Liao

Tse

. Immunomodulation by systemic administration of human-induced pluripotent stem cell-derived mesenchymal stromal cells to enhance the therapeutic efficacy of cell-based therapy for treatment of myocardial infarction. Theranostics. 2021;11(4):1641–54.

49.

Lian

Zhang

Lam

Kang

Xia

Lai

, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010;121(9):1113–23.

50.

Ogino

Hayashida

Yamakawa

Morita

. Adipose-derived stem cells promote intussusceptive lymphangiogenesis by restricting dermal fibrosis in irradiated tissue of mice. Int J Mol Sci. 2020;21(11):3885.

Efficacy of Neonatal Porcine Bone Marrow–Derived Mesenchymal Stem Cell Xenotransplantation for the Therapy of Hind Limb Lymphedema in Mice

Abstract

Keywords

Introduction

Materials and Methods

Study Design

Animals and Ethics

Induction of Hind Limb Lymphedema

Preparation of NpBM-MSCs

Quality Assessment of the NpBM-MSCs

Assessment of LEC Proliferation

Three-Dimensional Culture of LECs

MSC Xenotransplantation and Animal Groups

Measurements of Femoral Circumference and Hind Limb Volume

Histological Assessment of the Hind Limb

Measurement of Lymphatic Flow Using NIRF Imaging

Real-Time Quantitative Polymerase Chain Reaction

Statistical Analysis

Results

NpBM-MSCs Promote the Proliferation of LECs Via the Secretion of VEGFs

NpBM-MSC Xenotransplantation Ameliorates Lymphedema Via the Promotion of Lymphangiogenesis and a Recovery of Lymphatic Flow

Xenotransplanted NpBM-MSCs Increase the Expression of Both Porcine and Murine VEGFs Until They Are Rejected

Discussion

Footnotes

Acknowledgements

Data availability statement

Ethical Approval

Statement of Human and Animal Rights

Statement of Informed Consent

Declaration of Conflicting Interests

Funding

ORCID iDs

References